Iridex Corp. IRIX
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 1996 · data as of November 13, 2026
Iridex Corp. (IRIX) is a healthcare company listed in the US with a market value of about $12M. In the twelve months to July 4, 2026 it had revenue of $52M and net income of -$4M, a net margin of -6.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is track record (0/5).
Key numbers: 5-year revenue growth of 8% a year, a 5-year average ROIC of -54%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 42% above the current price.
About Iridex
Iridex is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 1996. Revenue went from $43M in 2014 to $53M in 2025, growth of about 1.9% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 6% over three years (dilution for shareholders). It spends 7% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52M | $53M | $49M | $52M | $57M | $54M | $36M | $43M | $43M | $42M | $46M |
| Net income | -$4M | -$4M | -$9M | -$10M | -$8M | -$5M | -$6M | -$9M | -$13M | -$13M | -$12M |
| Free cash flow | -$2M | -$2M | -$7M | -$7M | -$10M | $8M | -$3M | -$8M | -$10M | -$4M | -$1M |
| EPS (diluted) | $-0.20 | $-0.26 | $-0.54 | $-0.59 | $-0.47 | $-0.34 | $-0.46 | $-0.64 | $-1.05 | $-1.11 | $-1.15 |
| Net margin | -6.9% | -8.4% | -18.3% | -18.4% | -13.2% | -9.7% | -17.4% | -20.3% | -30.1% | -30.9% | -25.4% |
| ROIC | — | -35.5% | -115.0% | -64.4% | -31.4% | -22.9% | -25.6% | -27.4% | -33.9% | -41.8% | -5.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Iridex stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 42% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Iridex pay a dividend?
Not currently.
Is Iridex a good stock to buy?
We do not give buy or sell advice. Iridex scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.